TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28111716

Group type: EXPERIMENTAL
Intervention: Low-dose rituximab (250 mg/m2 given twice 1 week apart per cycle)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Retreatment with low-dose rituximab
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: One cycle of low-dose rituximab
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Two or more cycles of low-dose rituximab
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low-dose rituximab
Number of subjects: 37
Study: 25988270

Group type: EXPERIMENTAL
Intervention: Real Auricular Point Acupressure (APA) treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham Auricular Point Acupressure treatment
Number of subjects: 61
Study: 24120678

Group type: EXPERIMENTAL
Intervention: 2+1-dose group (PCV7 at 2, 4, and 11 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-dose group (PCV7 at 2 and 4 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster dose at 24 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: No PCV7 (controls)
Number of subjects: 0
Study: 21611896

Group type: EXPERIMENTAL
Intervention: Tongjiang granule (TJG) 10 g and mosapride citrate dummy 5 mg three times a day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mosapride citrate 5 mg and TJG dummy 10 g three times a day
Number of subjects: 120
Study: 18758777

Group type: EXPERIMENTAL
Intervention: CT-free CAOS
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: CT-based CAOS
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional TK
Number of subjects: 57
Study: 16687481

Group type: EXPERIMENTAL
Intervention: Salbutamol (12 mg/day for four weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15388279

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 16086881

Group type: EXPERIMENTAL
Intervention: China-made tropisetron hydrochloride (5 mg, intravenously)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Navoban (import tropisetron hydrochloride, intravenously)
Number of subjects: 132
Study: 10608948

Group type: EXPERIMENTAL
Intervention: Liquid nutrition supplement (six 235‐mL cans weekly)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 71
Study: 8527290

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2125513

Group type: EXPERIMENTAL
Intervention: Neutron treatment
Number of subjects: 165

Group type: COMPARATOR
Intervention: Photon treatment
Number of subjects: 165
Study: 295576

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of L-asparaginase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous administration of L-asparaginase
Number of subjects: 0
Study: 30789386

Group type: EXPERIMENTAL
Intervention: First-line ipilimumab (2010-2015)
Number of subjects: 2793

Group type: COMPARATOR
Intervention: First-line dacarbazine (2007-2009)
Number of subjects: 2793
Study: 28603362

Group type: EXPERIMENTAL
Intervention: Craniocervical flexion exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Suboccipitalis relaxation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 26518594

Group type: EXPERIMENTAL
Intervention: Unified Model of Performance (UMP) predictions based on psychomotor vigilance task (PVT) lapse data from CSR conditions (3, 5, 7, and 9 hours of sleep/night)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Unified Model of Performance (UMP) predictions for TSD and nap schedules
Number of subjects: 14
Study: 24667715

Group type: EXPERIMENTAL
Intervention: Combination treatment (EndoTAG‐1 22 mg/m(2) + paclitaxel 70 mg/m(2))
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: EndoTAG‐1 (2× 44 mg/m(2))
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Paclitaxel (90 mg/m(2))
Number of subjects: 140
Study: 21756154

Group type: EXPERIMENTAL
Intervention: Combination formulation (5% hexane extract of Curcuma aeruginosa + 5% minoxidil)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 5% minoxidil
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 5% Curcuma aeruginosa
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 18942100

Group type: EXPERIMENTAL
Intervention: Movement strategy training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Musculoskeletal exercises
Number of subjects: 0
Study: 16837516

Group type: EXPERIMENTAL
Intervention: Activating, structured treatment by social workers
Number of subjects: 194

Group type: COMPARATOR
Intervention: Routine GP care
Number of subjects: 194
Study: 15669588

Group type: EXPERIMENTAL
Intervention: Screening in four rounds every third year
Number of subjects: 9171

Group type: COMPARATOR
Intervention: Non-screening strategy (Control)
Number of subjects: 9171
Study: 12539884

Group type: EXPERIMENTAL
Intervention: Eucarbon (charcoal tablets)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Carbo ligni (CL)
Number of subjects: 284
Study: 9424977

Group type: EXPERIMENTAL
Intervention: Famciclovir, 500 mg orally twice daily for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 7656833

Group type: EXPERIMENTAL
Intervention: Single high dose DDP (Cisplatin)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Fractionated low doses DDP (Cisplatin)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 72
Study: 2569959

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Betaxolol (20 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Minoxidil (5.5 mg/day, added at week 6 if SDAP > 95 mm Hg)
Number of subjects: 40
Study: 30256919

Group type: EXPERIMENTAL
Intervention: Unstimulated plasma analytes
Number of subjects: 421

Group type: COMPARATOR
Intervention: Predictive model analysis using unstimulated analytes
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Unstimulated IL-2 and IFN-γ
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Background-adjusted values
Number of subjects: 421
Study: 27894198

Group type: EXPERIMENTAL
Intervention: 27 mg elemental iron daily (group I)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 54 mg elemental iron daily (group II)
Number of subjects: 120
Study: 25301007

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care interventions developed by the clinical pharmacist in collaboration with the physician
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual care without clinical pharmacist's input
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care interventions
Number of subjects: 106
Study: 24189342

Group type: EXPERIMENTAL
Intervention: Fluoxetine, 40 mg per day for 3 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 22963463

Group type: EXPERIMENTAL
Intervention: Below knee stockinette application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Above knee stockinette application
Number of subjects: 0
Study: 19297430

Group type: EXPERIMENTAL
Intervention: Low-fat diet (30.8% of energy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate-fat, high polyunsaturated fat diet (36.3% of energy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate in fat and saturated fat diet (37.9% of energy, 11.4% of energy respectively)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study: 17537204

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BiV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional right ventricular apical (RVA) pacing
Number of subjects: 200
Study: 15468944

Group type: EXPERIMENTAL
Intervention: Iodine concentration of 370 mg/mL (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iodine concentration of 300 mg/mL (Group A)
Number of subjects: 100
Study: 11161898

Group type: EXPERIMENTAL
Intervention: Community-acquired yeast carriage
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Hospital-acquired yeasts
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Healthcare workers colonization
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Person-to-person transmission
Number of subjects: 69
Study: 9630813

Group type: EXPERIMENTAL
Intervention: Salofalk (500 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pentasa (500 mg)
Number of subjects: 12
Study: 8310405

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (1 gm cephalothin intravenously 30 minutes before the procedure and 500 mg cephalexin orally every 6 hours for 3 days afterward)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 84
Study: 2646421

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (S&RP) with open flap procedure
Number of subjects: 114

Group type: COMPARATOR
Intervention: Scaling and root planing (S&RP) alone
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: More experienced operators
Number of subjects: 114

Group type: COMPARATOR
Intervention: Less experienced operators
Number of subjects: 114
Study: 4930389

Group type: EXPERIMENTAL
Intervention: Busulphan
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study: 30691442

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding combined with lifestyle interventions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined lifestyle interventions
Number of subjects: 60
Study: 26956782

Group type: EXPERIMENTAL
Intervention: Probiotics-supplemented group
Number of subjects: 60
Study: 25790882

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 322
Study: 23564395

Group type: EXPERIMENTAL
Intervention: Ending the discussion with a question (autonomy approach)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Ending the discussion with a recommendation (beneficence approach)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Patients who had chosen DNR for themselves
Number of subjects: 78

Group type: COMPARATOR
Intervention: Patients who had not chosen DNR for themselves
Number of subjects: 78
Study: 21703048

Group type: EXPERIMENTAL
Intervention: Tadalafil plus Vacuum Erection Device (VED), 10 minutes unbanded per day for at least 5 days weekly
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tadalafil plus Vacuum Erection Device (VED)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Tadalafil
Number of subjects: 23
Study: 17565213

Group type: EXPERIMENTAL
Intervention: Group reminiscence approach (GRA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Social contact
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (supportive care)
Number of subjects: 60
Study: 16093403

Group type: EXPERIMENTAL
Intervention: Powdered fermented milk with L. helveticus CM4 (12 g daily for 4 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (12 g daily for 4 weeks)
Number of subjects: 80
Study: 12174393

Group type: EXPERIMENTAL
Intervention: Ultrasonic aspiration hepatectomy (group T)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Conventional hepatectomy (group C)
Number of subjects: 315
Study: 10442275

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide at a dose of 2,400 micrograms daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Systemic corticosteroid (standard adjunctive therapy)
Number of subjects: 9
Study: 7792016

Group type: EXPERIMENTAL
Intervention: Hyperuricemia group (148 subjects with ischemic heart disease)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group (222 subjects without ischemic heart disease)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Hyperuricemia group with triglycerides > 200 mg/dl
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Whole group and males
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Females aged 60-69 years vs 70-79 years
Number of subjects: 370
Study: 2217030

Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg twice daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 883330

Group type: EXPERIMENTAL
Intervention: Simple mastectomy with pectoral lymph node biopsy
Number of subjects: 243

Group type: COMPARATOR
Intervention: Radical mastectomy plus radical radiotherapy
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Simple mastectomy
Number of subjects: 243
Study: 30413151

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg and 240 mg
Number of subjects: 270
Study: 26487585

Group type: EXPERIMENTAL
Intervention: IHC (Immunohistochemistry)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: IHC (Immunohistochemistry) with iScore 3
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: IHC-positive patients with atypical FISH pattern
Number of subjects: 436

Group type: COMPARATOR
Intervention: IHC staining intensity
Number of subjects: 436
Study: 24434887

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (9 mins per day, 5 days per week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional physical therapy exercise program (3 months)
Number of subjects: 30
Study: 22547995

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 212
Study: 20933640

Group type: EXPERIMENTAL
Intervention: Helical multidetector CT (MDCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential multidetector CT (MDCT)
Number of subjects: 0
Study: 18655983

Group type: EXPERIMENTAL
Intervention: Capsular bending ring (CBR) implantation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intraocular lens (IOL) implantation alone (no CBR)
Number of subjects: 60
Study: 15878726

Group type: EXPERIMENTAL
Intervention: Visual warning signal with random foreperiod (1.0‐6.5 s)
Number of subjects: 0
Study: 12648204

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.2% ropivacaine
Number of subjects: 40
Study: 11117682

Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 126

Group type: COMPARATOR
Intervention: Wire fixation
Number of subjects: 126
Study: 8959628

Group type: EXPERIMENTAL
Intervention: Interleukin-8
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: huGRO alpha
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: MCP-1
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: RANTES
Number of subjects: 5
Study: 1541613

Group type: EXPERIMENTAL
Intervention: Single 800-centigray dose of limited-field radiation
Number of subjects: 55

Group type: COMPARATOR
Intervention: 1000 centigray of limited-field radiation in divided doses
Number of subjects: 55

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 55
Study: 3993426

Group type: EXPERIMENTAL
Intervention: Iohexol 350 mg I/ml, 500 mg I/kg body weight
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metrizoate 350 mg I/ml, 500 mg I/kg body weight
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Iohexol and Metrizoate
Number of subjects: 20
Study: 29935583

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.5 ng ml‐1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Propofol (1.7 μg ml‐1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.9% end‐tidal)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: S-ketamine (0.75 μg ml‐1)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 27142970

Group type: EXPERIMENTAL
Intervention: Intra-articular TXA (IA group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intravenous TXA (IV group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No TXA (Control group C)
Number of subjects: 75
Study: 24262818

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 21917054

Group type: EXPERIMENTAL
Intervention: AA attendance
Number of subjects: 1726
Study: 20189555

Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) performed near the inner cell mass (ICM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assisted hatching (AH) at the side opposite to the ICM
Number of subjects: 0
Study: 18062586

Group type: EXPERIMENTAL
Intervention: Magnesium treatment
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Hypocalcaemia during treatment
Number of subjects: 137
Study: 15714933

Group type: EXPERIMENTAL
Intervention: 30 Gy in 10 fractions (regimen 2)
Number of subjects: 149

Group type: COMPARATOR
Intervention: 10 Gy single fraction (regimen 1)
Number of subjects: 149
Study: 11834357

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 86
Study: 10574605

Group type: EXPERIMENTAL
Intervention: S100
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HMB45
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: NKI
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: AAT
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CD68
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HAM56
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mac387
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Muramidase
Number of subjects: 43
Study: 8918628

Group type: EXPERIMENTAL
Intervention: Epo (150 U/kg.week s.c.)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-Epo treatment
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Epo treatment
Number of subjects: 29
Study: 1323587

Group type: EXPERIMENTAL
Intervention: MK-571 (450 mg total dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MK-571 (37.5 mg total dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6381167

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1600 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diclofenac 100 mg daily
Number of subjects: 50
Study: 30738912

Group type: EXPERIMENTAL
Intervention: Performance feedback
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Goal setting
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Both goal setting and performance feedback
Number of subjects: 4

Group type: COMPARATOR
Intervention: None (control)
Number of subjects: 4
Study: 29705803

Group type: EXPERIMENTAL
Intervention: Lipid-lowering pretreatment
Number of subjects: 3284

Group type: COMPARATOR
Intervention: Low-dose alteplase (0.6 mg/kg)
Number of subjects: 3284

Group type: COMPARATOR
Intervention: Standard-dose alteplase (0.9 mg/kg)
Number of subjects: 3284
Study: 28965385

Group type: EXPERIMENTAL
Intervention: Modified Jujing No.2 Decoction (1 dose a day, bid)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Danshen Tablets (4 tablets once, tid) plus Liu Wei Di Huang Wan (8 pills once, tid)
Number of subjects: 70
Study: 23869061

Group type: EXPERIMENTAL
Intervention: Sapropterin (10 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 21816634

Group type: EXPERIMENTAL
Intervention: Vacuum assist technique for glenoid fixation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group using modern 'third generation' cementing techniques
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study: 19536889

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) with LHRH-A plus bicalutamide 80 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: LHRH-A monotherapy
Number of subjects: 205
Study: 16690640

Group type: EXPERIMENTAL
Intervention: High Frequency Oscillatory Ventilation (HFOV)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Conventional Ventilation (CV)
Number of subjects: 585
Study: 14726728

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 19

Group type: COMPARATOR
Intervention: Pimozide
Number of subjects: 19
Study: 11770031

Group type: EXPERIMENTAL
Intervention: Steroid (250 mg of prednisolone)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Aprotinin (6 Mio. KIU)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Heparin coating of the artificial surface (Bioline)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard medication (control group)
Number of subjects: 160
Study: 9051894

Group type: EXPERIMENTAL
Intervention: 360 degrees lumbar fusion with decompression
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nonsurgery (control group)
Number of subjects: 81
Study: 7506452

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 31

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 31
Study: 2829953

Group type: EXPERIMENTAL
Intervention: Fenoterol (400, 600, 800 micrograms)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Salbutamol (400, 600, 800 micrograms)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both drugs (Fenoterol and Salbutamol)
Number of subjects: 6
Study: 29566816

Group type: EXPERIMENTAL
Intervention: CRT-On
Number of subjects: 807

Group type: COMPARATOR
Intervention: CRT-Off
Number of subjects: 807
Study: 26887029

Group type: EXPERIMENTAL
Intervention: Surgical consultation requested prior to PCI (n < 201)
Number of subjects: 427

Group type: COMPARATOR
Intervention: No surgical consultation requested prior to PCI (n < 226)
Number of subjects: 427
Study: 25036533

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 23085705

Group type: EXPERIMENTAL
Intervention: Light support (S1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High support (S4)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No electrical support (NO)
Number of subjects: 20
Study: 20022836

Group type: EXPERIMENTAL
Intervention: Genotype notification group (intervention group)
Number of subjects: 562

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 562
Study: 18662961

Group type: EXPERIMENTAL
Intervention: Wrist Ratio (WR) > or = 0.70
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Wrist Palm Ratio > 0.342
Number of subjects: 67